Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2025 · 10-Q
Revenue$121.00K$121.00K−25.8% vs Q2 2024 Net Income-$13.94M-$13.94MN/M vs Q2 2024 EPS Diluted-$0.21-$0.21N/M vs Q2 2024 Operating Income-$14,777,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-12212.4%−4516.1 pt vs Q2 2024
Net margin-11523.1%−4297.4 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 29, 2025 · 29 d after period end